BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.090
+0.030 (1.46%)
Sep 8, 2025, 2:08 PM - Market open
BioCardia Revenue
In the year 2024, BioCardia had annual revenue of $58.00K, down -87.84%.
Revenue (ttm)
$58.00K
Revenue Growth
-87.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
12.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BCDA News
- 4 days ago - BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 - GlobeNewsWire
- 27 days ago - BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 weeks ago - BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - GlobeNewsWire
- 5 weeks ago - BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter - GlobeNewsWire
- 3 months ago - BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - GlobeNewsWire
- 4 months ago - BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire